The PI3K pathway as drug target in human cancer

Kevin D. Courtney, Ryan B. Corcoran, Jeffrey A. Engelman

Research output: Contribution to journalReview article

878 Scopus citations

Abstract

The phosphatidylinositol 3-kinase (PI3K) signaling axis impacts on cancer cell growth, survival, motility, and metabolism. This pathway is activated by several different mechanisms in cancers, including somatic mutation and amplification of genes encoding key components. In addition, PI3K signaling may serve integral functions for noncancerous cells in the tumor microenvironment. Consequently, therapeutics targeting the PI3K pathway are being developed at a rapid pace, and preclinical and early clinical studies are beginning to suggest specific strategies to effectively use them. However, the central role of PI3K signaling in a large array of diverse biologic processes raises concerns about its use in therapeutics and increases the need to develop sophisticated strategies for its use. In this review, we will discuss how PI3K signaling affects the growth and survival of tumor cells. From this vantage, we will consider how inhibitors of the PI3K signaling cascade, either alone or in combination with other therapeutics, can most effectively be used for the treatment of cancer.

Original languageEnglish (US)
Pages (from-to)1075-1083
Number of pages9
JournalJournal of Clinical Oncology
Volume28
Issue number6
DOIs
StatePublished - Feb 20 2010

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this